Randomised Controlled Trial Comparing Rituximab to Mycophenolate Mofetil in Children and Young Adults with Steroid-Dependent Idiopathic Nephrotic Syndrome



Methods



Multicenter, open label, 2 parallel arm study



Superiority controlled RCT



Aged 2 - 24 years



Steroid dependent idiopathic nephrotic syndrome



MMF 1200 mg/m² N = 70



26 %

Primary endpoint Recurrence of nephrotic syndrome

OR - 1.45 (95% CI 0.8 to 2.7)

Results (2 years follow up)

37%

Glucocorticoids tapered till withdrawal



No severe adverse effects in both arms

Angeletti et al.

VA by Krithika Mohan, MD, DNB

@krithicism

Conclusion: A single dose of rituximab was not superior to MMF in maintaining remission at 2 year of follow-up in children and young adults with steroid-dependent nephrotic syndrome.

